Literature DB >> 31488250

Age-Dependent Prognostic Impact of Paroxysmal Versus Sustained Atrial Fibrillation on the Incidence of Cardiac Death and Heart Failure Hospitalization (the Fushimi AF Registry).

Yoshimori An1, Hisashi Ogawa1, Masahiro Esato2, Mitsuru Ishii1, Moritake Iguchi1, Nobutoyo Masunaga1, Yuya Aono1, Syuhei Ikeda1, Kosuke Doi1, Hikari Tsuji3, Hiromichi Wada4, Koji Hasegawa4, Mitsuru Abe1, Gregory Y H Lip5, Masaharu Akao6.   

Abstract

Data regarding the relation of the type of atrial fibrillation (AF) to the incidence of cardiac events remain scarce. This study sought to investigate the association of AF type with the incidences of cardiac death and heart failure (HF) hospitalization between paroxysmal and sustained (persistent/permanent) AF in the overall population and in age subgroups (≤74, 75 to 84, and ≥85 years), using the data from a Japanese community-based prospective survey, the Fushimi AF Registry. The participants started to be enrolled since March 2011, and follow-up data were available for 4,304 patients by the end of November 2017. Patients with sustained AF (n = 2,187, 50.8%) had more co-morbidities with higher mean CHA2DS2-VASc score than those with paroxysmal AF (n = 2,117, 49.2%) (sustained vs paroxysmal: 3.57 ± 1.69 vs 3.17 ± 1.67, p <0.001). During a median follow-up of 1,307 (interquartile range: 709 to 2,156) days, the composite of cardiac death and HF hospitalization occurred more frequently in those with sustained AF (event rate: 5.1 vs 2.8 per 100 person-years; p <0.001). On multivariate analysis, sustained AF was independently associated with higher incidence of this composite end point (adjusted hazard ratio [HR]: 1.35, 95% confidence interval [CI]: 1.12 to 1.63, p = 0.002). In age subgroups, this association was observed only in the younger AF patients (≤74 years) (adjusted HR: 2.03, 95% CI: 1.44 to 2.86, p <0.001), but not in the older subgroups (p = 0.018 for interaction). In conclusion, sustained AF was associated with higher incidence of the composite of cardiac death and HF hospitalization than paroxysmal AF, with different relations seen depending on age subgroups.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31488250     DOI: 10.1016/j.amjcard.2019.07.048

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  2 in total

1.  Paroxysmal and Non-Paroxysmal Atrial Fibrillation in Middle Eastern Patients: Clinical Features and the Use of Medications. Analysis of the Jordan Atrial Fibrillation (JoFib) Study.

Authors:  Hanna Al-Makhamreh; Nasr Alrabadi; Lubna Haikal; Mohammad Krishan; Noor Al-Badaineh; Osama Odeh; Tawfiq Barqawi; Mohammed Nawaiseh; Ala Shaban; Basil Abdin; Lama Khamies; Ayman Hammoudeh
Journal:  Int J Environ Res Public Health       Date:  2022-05-19       Impact factor: 4.614

2.  Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF.

Authors:  Sergio J Dubner; Christine Teutsch; Menno V Huisman; Hans-Christoph Diener; Jonathan Halperin; Kenneth J Rothman; Chang-Sheng Ma; Eduardo Chuquiure-Valenzuela; Jutta Bergler-Klein; Kristina Zint; Lionel Riou França; Shihai Lu; Miney Paquette; Gregory Y H Lip
Journal:  ESC Heart Fail       Date:  2020-07-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.